米维布塞 T3712
面议
- TargetMol
- 生产商
- 进口
- 美国
- 现货
- 全国
- 8
- 0
Product IntroductionBioactivity英文名: Mivebresib描述: Mivebresib (ABBV-075) 是一种有效的，口服活性的溴结构域和末端结构域 (BET) 抑制剂，结合BRD4的Ki 值是 1.5
AI问答
配套的仪器设备？
可以搭配的相关耗材试剂？
耗材描述
Product Introduction
Bioactivity
英文名: Mivebresib
描述: Mivebresib (ABBV-075) 是一种有效的，口服活性的溴结构域和末端结构域 (BET) 抑制剂，结合BRD4的Ki 值是 1.5 nM。
体外活性: ABBV-075 exhibits robust single agent activity in cell viability assays across cancer cell lines derived from solid tumors, leukemia and lymphomas. It could disrupt cell cycle control leading to G1 arrest followed by senescence, inhibit oncogenesis drivers leading to apoptosis, and potentially target tumor microenvironment to provide additional therapeutic benefit[1].
体内活性: ABBV-075 has comparable or superior efficacies to standard of care agents in flank xenograft mouse models of non-small-cell and small cell lung cancers, pancreatic, breast, prostate, head & neck cancers, multiple myeloma, diffuse large B cell lymphoma and leukemia[1].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 84 mg/mL (183 mM)
关键字: ABBV 075 | Mivebresib | ABBV075 | Inhibitor | Apoptosis | Epigenetic Reader Domain | inhibit
相关产品: LYN-1604 dihydrochloride | Tubulin inhibitor 11 | Masitinib | Orlistat | Garcinol | Tolcapone | SC99 | Isovalerylcarnitine | MG 149 | Enpp/Carbonic anhydrase-IN-2
相关库: Drug Repurposing Compound Library | ReFRAME Related Library | Anti-Cancer Drug Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | Highly Selective Inhibitor Library | PPI Inhibitor Library | Target-Focused Phenotypic Screening Library | NO PAINS Compound Library
Bioactivity
英文名: Mivebresib
描述: Mivebresib (ABBV-075) 是一种有效的，口服活性的溴结构域和末端结构域 (BET) 抑制剂，结合BRD4的Ki 值是 1.5 nM。
体外活性: ABBV-075 exhibits robust single agent activity in cell viability assays across cancer cell lines derived from solid tumors, leukemia and lymphomas. It could disrupt cell cycle control leading to G1 arrest followed by senescence, inhibit oncogenesis drivers leading to apoptosis, and potentially target tumor microenvironment to provide additional therapeutic benefit[1].
体内活性: ABBV-075 has comparable or superior efficacies to standard of care agents in flank xenograft mouse models of non-small-cell and small cell lung cancers, pancreatic, breast, prostate, head & neck cancers, multiple myeloma, diffuse large B cell lymphoma and leukemia[1].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 84 mg/mL (183 mM)
关键字: ABBV 075 | Mivebresib | ABBV075 | Inhibitor | Apoptosis | Epigenetic Reader Domain | inhibit
相关产品: LYN-1604 dihydrochloride | Tubulin inhibitor 11 | Masitinib | Orlistat | Garcinol | Tolcapone | SC99 | Isovalerylcarnitine | MG 149 | Enpp/Carbonic anhydrase-IN-2
相关库: Drug Repurposing Compound Library | ReFRAME Related Library | Anti-Cancer Drug Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | Highly Selective Inhibitor Library | PPI Inhibitor Library | Target-Focused Phenotypic Screening Library | NO PAINS Compound Library
猜你喜欢
感兴趣产品